glp-1 drugs with least side effects GLP-1s for Weight Loss: What You Need to Know Part 2 of a 3-Part

In a Phase II readout released in August 2022, the pharma touted a 15.6% drop in body weight in patients taking CagriSema, versus 5.1% in comparators on semaglutide alone and 8.1% in patients treated with only cagrilintide

Glucagon-like peptide-1 (GLP-1) receptor agonists are medications approved by the FDA for managing type 2 diabetes and, in some formulations, for chronic weight management

Pamir N, Lynn FC, Buchan AM, Ehses J, Hinke SA, Pospisilik JA, Miyawaki K, Yamada Y, Seino Y, McIntosh CH, et al

It can also be easier for insurance companies to cover bariatric surgery due to it being a one-time, permanent solution for weight loss, rather than an ongoing medication